MALVERN, Pa., May 9, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended March 31, 2011. For the first quarter of 2011, Auxilium reported net revenues of $58.4 million compared to net revenues of $45.5 million in the first quarter of 2010. The net loss for the first quarter of 2011 was $(11.8) million, or $(0.25) per share, compared to a net loss of $(8.6) million, or $(0.18) per share, reported for the first quarter of 2010.
"We are pleased with the steady progress we made in the first quarter of 2011. XIAFLEX showed double-digit growth compared to the fourth quarter of 2010, our European partner, Pfizer, received EMA approval for XIAPEX® for Dupuytren's contracture and we signed an agreement with Asahi Kasei Pharma for development of XIAFLEX in Japan," said Armando Anido, Chief Executive Officer and President of Auxilium. "We continue to be encouraged by the success stories that we receive from patients, physicians and payers on XIAFLEX use. Testim also continues to perform well with 9% U.S. prescription growth year over year in the first quarter."
First Quarter and Recent Operational Highlights: XIAFLEX:
|SOURCE Auxilium Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved